Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
But efficacy still needs to go up, as several groups try to combine PD-1 and CTLA-4 using differing approaches.
The Merck & Co drug's first successful phase 3 study might not be all it’s cracked up to be.
Early data on Hansoh’s HS-20089 were enough to tempt GSK, but Seagen isn't far behind.
Astra manages to avoid the toxicities that scuppered Lilly’s PD-1 x TIM-3 contender, but still needs to dial up sabestomig’s efficacy.
But toxicity will be closely watched in future trials.
The numerical survival benefit versus Keytruda underperform’s Merck’s phase 3 study, but there’s a possible reason for that.